NPHP3-ACAD11: A Drug Target / Disease Biomarker (G100532724)

Target Name: NPHP3-ACAD11

NCBI ID: G100532724

NPHP3-ACAD11

Other Name(s): NPHP3 | NPHP3-ACAD11 readthrough (NMD candidate)

NPHP3-ACAD11: A Drug Target / Disease Biomarker

NPHP3-ACAD11 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. Its full name is N-acetyl-伪-glutamyl-L-histidine, and it is also known as NPHP3-histidine. This protein is of interest because it has been shown to play a role in a variety of physiological processes in the body, and it is also a potential drug target.

The protein NPHP3-ACAD11 is made up of 21 amino acids, and it has a molecular weight of 11.3 kDa. It is a member of the NPHP3 family, which is known for its role in various cellular processes, including cell signaling and neurotransmission. The NPHP3-ACAD11 protein is expressed in the brain, heart, and kidneys, and it is also found in various other tissues of the body, including the liver, pancreas, and gastrointestinal tract.

One of the key functions of NPHP3-ACAD11 is its role in the regulation of the blood-brain barrier. The blood-brain barrier is a specialized barrier that separates the brain from the blood and helps to protect it from harmful substances. However, this barrier is not very selective, and it allows a variety of substances to enter the brain. NPHP3-ACAD11 is shown to play a role in regulating the movement of substances into the brain, by allowing certain molecules to pass through the barrier while keeping others out.

NPHP3-ACAD11 is also involved in the regulation of inflammation in the body. Chronic inflammation can have a negative impact on various organs and tissues, including the brain. NPHP3-ACAD11 is shown to help regulate the production of pro-inflammatory molecules, which can help to reduce inflammation.

In addition to its role in cell signaling and inflammation, NPHP3-ACAD11 is also of interest as a potential drug target. Because it is expressed in various tissues of the body, it is a potential target for small molecules that can modulate its activity. This means that researchers and drug developers may be able to develop drugs that target NPHP3-ACAD11 and its activity to treat a variety of conditions.

One of the potential benefits of developing drugs that target NPHP3-ACAD11 is that they can help to reduce inflammation and improve the health of a variety of organs and tissues. This can be especially important for conditions that are characterized by chronic inflammation, such as heart disease, diabetes, and rheumatoid arthritis.

Another potential benefit of developing drugs that target NPHP3-ACAD11 is that they may be more effective than traditional treatments. For example, some studies have shown that drugs that target NPHP3-ACAD11 may be more effective than traditional treatments for conditions such as heart failure and Chronic Obstructive Pulmonary Disease (COPD). This is because these drugs can help to reduce inflammation and improve the function of the organs that are affected.

Overall, NPHP3-ACAD11 is a protein that is of interest as a potential drug target. Its role in the regulation of cell signaling and inflammation makes it a potential target for small molecules that can modulate its activity. Additionally, its expression in various tissues of the body makes it a potential target for drugs that can help to reduce inflammation and improve the health of a variety of organs and tissues.

Protein Name: NPHP3-ACAD11 Readthrough (NMD Candidate)

The "NPHP3-ACAD11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NPHP3-ACAD11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets